Dr Anju Kulkarni

Dr Anju Kulkarni

MBBS(Hons) BSc(Hons) MD(Res) FRCP

About Me

I am a Consultant Clinical Geneticist at Guy’s and St Thomas’ Hospital. I graduated with distinctions in Medicine and Pathology from Imperial College, School of Medicine and subsequently trained at a specialist level in both Medical Oncology, at University College London Hospital, and Clinical Genetics at Guy’s and St Thomas’ Hospital, the Kennedy – Galton centre and the Royal Marsden Hospital. I have developed several guidelines for the management of individuals with an inherited susceptibility to cancer, including an internationally recognised Cancer Genetics app for healthcare professionals, and lead multidisciplinary specialist clinical for BRCA1/2 gene mutation carriers and other rarer hereditary cancer conditions. I am a member of the Sarah Cannon Research Institutes’ Genomic Review Board and medical advisor to the UK Genetic Counselling Registration Board. I have extensive clinical and academic experience in Cancer Genetics and have published, presented and taught on the topic at national and international level.


Research and Publications

Selected Publications

Hereditary breast cancer genetics and risk prediction techniques. Kulkarni A, Carley H. In: Multidisciplinary management of breast cancer for surgeons: A European textbook, 2018

Advances in the recognition and management of hereditary cancer. Kulkarni A, Carley H. Brit Med Bull (2016) 120(1): 123-138

Management of women with a genetic predisposition to gynaecological cancer. Kulkarni A, Brady AF. Royal College of Obstetricians and Gynaecologists Scientific Impact Paper no 48 Feb 2015

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Mavaddat et al. J Natl Cancer Inst (2013) 105(11): 812-22

Cdc7 kinase is a predictor of survival and novel therapeutic target in epithelial ovarian carcinoma. Kulkarni A, Kingsbury S, TudzarovaTrajkovska S et al. Clin Cancer Res (2009) 15(7): 2417-25

DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Kulkarni A, Loddo M, Leo E et al. Clin Cancer Res (2007) 13(20): 6153-61

LOC 95 Harley Street